Zhi Tong Cai Jing·2025-10-26 08:03Core Insights - WuXi AppTec (603259.SH) reported a revenue of RMB 32.857 billion for the first three quarters of 2025, representing a year-on-year growth of 18.61% [1] - The net profit attributable to shareholders reached RMB 12.076 billion, showing a significant increase of 84.84% year-on-year [1] - The net profit after deducting non-recurring gains and losses was RMB 9.522 billion, up by 42.51% year-on-year [1] Group 1: Chemical Business - The chemical business generated revenue of RMB 25.98 billion, reflecting a year-on-year growth of 29.3% [1] - The small molecule drug discovery ("R") business has successfully synthesized and delivered over 430,000 new compounds to clients in the past twelve months [1] - In the first three quarters of 2025, the company converted 250 molecules from research to development [1] Group 2: Small Molecule Development and Manufacturing (D&M) - The small molecule D&M business achieved revenue of RMB 14.24 billion, with a year-on-year increase of 14.1% [2] - A total of 621 new molecules were added to the small molecule D&M pipeline in the first three quarters of 2025, bringing the total to 3,430, which includes 80 commercial projects and 87 Phase III clinical projects [2] - The company successfully passed FDA inspections at its Changzhou and Taixing API bases with zero defects in March 2025 [2] Group 3: TIDES Business - The TIDES business (oligonucleotides and peptides) experienced rapid growth, with revenue reaching RMB 7.84 billion, a year-on-year increase of 121.1% [3] - As of September 2025, TIDES' order backlog grew by 17.1% year-on-year [3] - The number of clients served in TIDES D&M increased by 12%, and the number of molecules served rose by 34% [3]